Notable Representations, Key Contacts
We coordinate multi-jurisdictional filings to assure maximum chances for swift approval and protect our clients against the adverse effects of mergers through effective advocacy before various governmental agencies.
We help clients structure transactions and business practices that minimize antitrust concerns. Collaborating with lawyers in practices including Mergers & Acquisitions, Intellectual Property, Restructuring, and Corporate Governance, we provide integrated solutions to competition-related business issues.
Former Government Officials
This background provides the group with unmatched experience and insight into the merger review process and the substantive analysis that will be applied to transactions in these and other industries.
Shaping U.S. Antitrust Policy
With competition lawyers in the United States, European Union, China, and Eastern Europe, Weil has the international reach and experience to handle multinational reviews of mergers and acquisitions.
In countries where we do not have offices, we have developed strong and effective collaborative relationships with the best local competition law firms.
- Abbott Labs
- Applied Materials
- Array Biopharma
- C.R. Bard
- Eli Lilly
- Health Management Associates
- Jazz Pharmaceuticals
- Johnson & Johnson
- Kinder Morgan
- Providence Equity
- Sherwin Williams
- TH Lee
Complex transactions across an array of industries
Represented AbbVie, a global biopharmaceutical company, in its acquisition of Pharmacyclics, Inc., a transaction valued at $21 billion and which closed without the U.S. Federal Trade Commission issuing a Second Request.
Weil represented Actavis plc in antitrust matters concerning its $66 billion acquisition of Allergan, Inc.
Weil previously represented Forest Laboratories in connection with the worldwide antitrust review of the sale of the company to Actavis. The transaction was valued at approximately $25 billion.
Weil is representing Biomet in connection with the antitrust review of the sale of the company to Zimmer in a transaction valued at approximately $13.35 billion.
Weil has represented C. R. Bard, Inc. in its acquisition of SenoRx, Inc. for approximately $213 million. By combining their respective businesses, the transaction enabled the parties to offer a broader, more complete line of breast care products and deliver other benefits to hospitals, doctors, and patients. The matter received early termination from the Federal Trade Commission without issuance of a Second Request.
Weil has successfully represented Health Management Associates, Inc. (HMA) in connection with the antitrust review of the sale of the company to Community Health Systems, Inc. for approximately $7.6 billion. The two companies were leading operators of hospitals and other healthcare facilities in the United States. The transaction represented one of the largest mergers in the history of the U.S. hospital industry, and reportedly created the nation’s largest hospital company, with 206 facilities, and the second-largest by revenue, with $18.9 billion.
Weil has successfully represented Johnson & Johnson before the Federal Trade Commission in its $21.3 billion acquisition of Synthes, Inc., the largest acquisition in J&J’s history. Weil also coordinated the worldwide competition clearance process.
Weil also successfully represented J&J before the antitrust authorities in numerous other major transactions, including its $16.6 billion acquisition of Pfizer's consumer healthcare business and its attempted $20+ billion acquisition of Guidant Corporation.
Weil is representing J&J in its proposed $1.99 billion sale of its Cordis business, to Cardinal Health, Inc.
Weil has represented Kinder Morgan in its $38 billion acquisition of El Paso Corporation, owner of North America’s most extensive interstate natural gas pipeline system and one of North America’s biggest independent exploration and production companies. This deal created one of the largest energy companies in the world.
Weil successfully secured clearance for Signet Jewelers Limited, the largest retail jeweler in the United States and the United Kingdom, in the company’s $1.4 billion acquisition of Zale Corporation, a leading retailer of fine jewelry in North America.
- Weil has represented Staples, Inc. and Staples Acquisition B.V., in the United States and European Union, in connection with its unsolicited multi-billion dollar cash bid to acquire Corporate Express N.V. Weil obtained antitrust clearance in the United States and the European Union, and also coordinated the worldwide competition clearance filings.
Weil represented Walgreens and secured antitrust approval for its $23.8 billion acquisition of the 55% it did not already own of Alliance Boots GmbH (Switzerland), and in its previous purchase of a 45% interest in Alliance Boots, the largest acquisition in Walgreen’s company history.
Weil, in an earlier transaction, successfully represented Walgreens in connection with the company’s (and Alliance Boots’) acquisition of an equity position in AmerisourceBergen (one of the nation’s leading drug wholesalers), and the strategic, long-term alliance between the three companies. As part of this transaction, Walgreens entered into a 10-year comprehensive distribution agreement with AmerisourceBergen and provided AmerisourceBergen access to Walgreens and Alliance Boots’ recently established joint venture to purchase generic and branded pharmaceuticals.
This highly complex and innovative transaction was reviewed in multiple jurisdictions and raised a wide range of potential issues. As a result of our substantial industry expertise and effective advocacy, Weil was able to successfully coordinate the global antitrust process and obtain unconditional clearance for the transaction without a Second Request.
Also successfully represented Walgreens before the antitrust authorities in numerous other transactions, including the company's $1.1 billion acquisition of Duane Reade.
Weil Named Antitrust Firm of the Year
Legal Media Group’s Life Sciences Awards 2016
Weil’s Antitrust Practice Ranked Among the “Global Elite”
GCR 100 2016
Head of the Competition/Antitrust practice, Steven Newborn, and Antitrust partner, Steven Bernstein named “Trailblazers” by The National Law Journal
Achieved “outstanding” ranking in survey of Washington, D.C. antitrust bar
Global Competition Review, 2015
Weil's Antitrust practice has all the know-how and horsepower, but they also have a pragmatic and reasoned approach."
They have a very clear understanding of what the process looks like, how to get to the answers, and really how to get what their client wants."